Felix Geissler
Plus aucun poste en cours
Profil
Felix Geissler served as Vice President-Medical Affairs at Curis, Inc. in 2022-2023.
Prior to that, he held the same position at Horizon Therapeutics Plc.
He also served as Chief Medical Officer at Lumicell, Inc. and as SVP, Head-Oncology, Hematology & Transplant at Sanofi Corp.
Geissler holds a doctorate degree from the University of Innsbruck, Eberhard Karls Universität Tübingen, and Ludwig-Maximilians-Universität München.
Anciens postes connus de Felix Geissler
Sociétés | Poste | Fin |
---|---|---|
CURIS, INC. | Directeur Technique/Scientifique/R&D | 01/01/2023 |
Sanofi Corp. | Corporate Officer/Principal | - |
Lumicell, Inc.
Lumicell, Inc. Electronic Equipment/InstrumentsElectronic Technology Lumicell, Inc. develops and markets image-guided cancer surgery solutions. It offers Lumicell System, designed to enable surgeons to see residual cancer cells in the cavity walls in real-time during surgery. The company was founded by Linda G. Griffith, David G. Kirsch, Jorge M. Ferrer, Ralph Weissleder, W. David Lee, Andrey J. Zarur, and Moungi G. Bawendi in 2008 and is headquartered in Wellesley, MA. | Directeur Technique/Scientifique/R&D | - |
HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY | Directeur Technique/Scientifique/R&D | - |
Formation de Felix Geissler
Eberhard Karls Universität Tübingen | Doctorate Degree |
University of Innsbruck | Doctorate Degree |
Ludwig-Maximilians-Universität München | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 1 |
---|---|
CURIS, INC. | Health Technology |
Entreprise privées | 3 |
---|---|
Horizon Therapeutics Plc
Horizon Therapeutics Plc Pharmaceuticals: MajorHealth Technology Horizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland. | Health Technology |
Lumicell, Inc.
Lumicell, Inc. Electronic Equipment/InstrumentsElectronic Technology Lumicell, Inc. develops and markets image-guided cancer surgery solutions. It offers Lumicell System, designed to enable surgeons to see residual cancer cells in the cavity walls in real-time during surgery. The company was founded by Linda G. Griffith, David G. Kirsch, Jorge M. Ferrer, Ralph Weissleder, W. David Lee, Andrey J. Zarur, and Moungi G. Bawendi in 2008 and is headquartered in Wellesley, MA. | Electronic Technology |
Sanofi Corp. |